MUMBAI (Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday that U.S. regulators plan to lift a ban on its Mohali plant in Punjab, allowing the company to restart supplies from there after four years.
Sun gained the plant along with its acquisition of Ranbaxy Laboratories in 2015 and has been attempting to fix quality control problems there that the U.S. Food and Drug Administration (FDA) identified in 2013.
Sun said the FDA informed it on Monday that it plans to lift the ban. "This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the U.S. market, subject to normal U.S. FDA regulatory requirements," the company said in a statement to stock exchanges.
Sun's shares were up 6 percent at 722 rupees at 8:22 GMT in Mumbai on Tuesday.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Muralikumar Anantharaman)
Disclaimer: No Business Standard Journalist was involved in creation of this content
